TOP > 外国特許検索 > MONOCLONAL ANTIBODY AGAINST EBAG9, HYBRIDOMA, AND APPLICATION FOR MONOCLONAL ANTIBODY AGAINST EBAG9

MONOCLONAL ANTIBODY AGAINST EBAG9, HYBRIDOMA, AND APPLICATION FOR MONOCLONAL ANTIBODY AGAINST EBAG9

外国特許コード F140008005
整理番号 S2012-1179-C0
掲載日 2014年10月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP074452
国際公開番号 WO 2014042167
国際出願日 平成25年9月11日(2013.9.11)
国際公開日 平成26年3月20日(2014.3.20)
優先権データ
  • 特願2012-199412 (2012.9.11) JP
発明の名称 (英語) MONOCLONAL ANTIBODY AGAINST EBAG9, HYBRIDOMA, AND APPLICATION FOR MONOCLONAL ANTIBODY AGAINST EBAG9
発明の概要(英語) A monoclonal antibody against EBAG9, said monoclonal antibody being obtained by a method including: a step in which a polypeptide is administered to a mouse as an immunogen, said polypeptide containing the amino acid sequence set forth in SEQ ID No. 1, and not containing the full-length amino acid sequence of EBAG9 protein; a step in which antibody-producing cells are collected from the mouse; a step in which an antibody-producing cell and a myeloma are fused to produce a hybridoma; a step in which an antibody produced by the hybridoma is brought into contact with a polypeptide containing the amino acid sequence set forth in SEQ ID No. 1, and not containing the full-length amino acid sequence of EBAG9 protein, and then a hybridoma is selected that produces an antibody that binds to the polypeptide containing the amino acid sequence set forth in SEQ ID No. 1, and not containing the full-length amino acid sequence of EBAG9 protein; and a step in which antibodies produced by the selected hybridoma are collected.
従来技術、競合技術の概要(英語) BACKGROUND ART
Breast cancer, many women over the age of 40, is an increasing trend in Japan. And said breast cancer is, estrogen receptor positive is often, endocrine therapy such as anti-estrogen agent endocrine therapy is the use of the drugs is known. However, in breast cancer, in the course of treatment, drug resistance to endocrine therapy to obtain many (resistance), and therefore a poor prognosis in question. Therefore, resistance to endocrine therapy to obtain breast cancer diagnosed at an early stage whether or not a technique capable of is demanded.
EBAG9 (Estrogen receptor-binding fragment associated gene 9) is, isolated as estrogen response gene, in later studies, involved in sugar chain modification of cancer cells, avoid from the immune system are shown to be involved. In addition, is EBAG9, breast cancer, ovarian cancer, prostate cancer, liver cancer, renal cancer, bladder cancer, testicular tumor, brain tumor, uterine cancer, thyroid cancer, gallbladder cancer, bile duct cancer, pancreatic cancer, colon cancer, gastric cancer, esophageal cancer, lung cancer, throat pharyngeal cancer, squamous cell carcinoma, malignant lymphoma, malignant mesothelioma, Paget's disease has been reported expression, the progression of a cancer, thought to be involved in metastasis.
So far, as an immunogen, using the entire length of the EBAG9, and developed a polyclonal antibody against EBAG9, wherein the polyclonal antibody immunostaining with breast cancer sample analysis is performed according to the method (for example, see non-patent document 1). The analysis, immunostaining of-EBAG9, estrogen receptor can be correlated to immunostaining, as well as CD3 positive tumor cell infiltration into the tissue can be correlated with an decreased T is shown. However, resistance to endocrine therapy of breast cancer such as whether or not to obtain the relationship between the prognosis of breast cancer, not yet been elucidated.
Therefore, resistance to endocrine therapy to obtain breast cancer diagnosed at an early stage whether or not a technique capable of not developed yet, its rapid development strongly demanded.
In addition, EBAG9 is as described above, breast cancer, ovarian cancer, prostate cancer, liver cancer, renal cancer, bladder cancer, testicular tumor, brain tumor, uterine cancer, thyroid cancer, gallbladder cancer, bile duct cancer, pancreatic cancer, colon cancer, gastric cancer, esophageal cancer, lung cancer, throat pharyngeal cancer, squamous cell carcinoma, malignant lymphoma, malignant mesothelioma, Paget's disease have been reported and expression, antibodies to EBAG9 can be effective in the treatment of cancer prevention to what would be considered of, yet such antibodies may be not provided.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAITAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • INOUE, Satoshi
  • IKEDA, Kazuhiro
  • IJICHI, Nobuhiro
  • SHIGEKAWA, Takashi
  • TSUDA, Hitoshi
  • MIYAZAKI, Toshiaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close